News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Trevena, Inc. (TRVN) Highlights Phase 2b-BLAST AHF Trial For TRV027 At The European Society Of Cardiology Heart Failure 2014 Meeting


5/19/2014 6:55:04 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Trevena, Inc. (NASDAQ: TRVN), a clinical stage pharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced that it presented the trial design rationale for its ongoing Phase 2b BLAST-AHF Study of TRV027 in acute heart failure (AHF) at the European Society of Cardiology Heart Failure (ESC-HF) 2014 Meeting, which is taking place May 17 – 20, 2014 in Athens, Greece.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES